UM  > 中華醫藥研究院
Investigational Hypoxia-Activated Prodrugs: Making Sense of Future Development
Min-Xia Su1; Le-Le Zhang1; Zhang-Jian Huang2; Jia-Jie Shi1; Jin-Jian Lu1
2018
Source PublicationCurrent Drug Targets
ISSN1873-5592
Volume20
Abstract

Hypoxia, which occurs in most cancer cases, disrupts the efficacy of anticarcinogens. Fortunately, hypoxia itself is a potential target for cancer treatment. Hypoxia-activated prodrugs (HAPs) can be selectively activated by reductase under hypoxia. Some promising HAPs have been already achieved, and many clinical trials of HAPs in different types of cancer are ongoing. However, none of them has been approved in clinic to date. From the studies on HAPs began, some achievements are obtained but more challenges are put forward. In this paper, we reviewed the research progress of HAPs to discuss the strategies for HAPs development. According to the research status and results of these studies, administration pattern, reductase activity, and patient selection need to be taken into consideration to further improve the efficacy of existing HAPs. As the requirement of new drug research and development, design of optimal preclinical models and clinical trials are quite important in HAPs development, while different drug delivery systems and anticancer drugs with different mechanisms can be sources of novel HAPs.

KeywordHypoxia-activated Prodrug Topoisomerase Ii Inhibitors Dna Alkylating Agents Targeted Drugs Reductases Activity Patient Selection Clinical Progress
DOIhttps://doi.org/10.2174/1389450120666181123122406
Language英语
Fulltext Access
Citation statistics
Document TypeJournal article
CollectionInstitute of Chinese Medical Sciences
Affiliation1.State Key Laboratory of Quality Research in Chinese Medicine, Institute of Chinese Medical Sciences, University of Macau, Macao, China
2.State Key Laboratory of Quality Research in Chinese Medicine, Institute of Chinese Medical Sciences, University of Macau, Macao, China
First Author AffilicationInstitute of Chinese Medical Sciences
Recommended Citation
GB/T 7714
Min-Xia Su,Le-Le Zhang,Zhang-Jian Huang,et al. Investigational Hypoxia-Activated Prodrugs: Making Sense of Future Development[J]. Current Drug Targets,2018,20.
APA Min-Xia Su,Le-Le Zhang,Zhang-Jian Huang,Jia-Jie Shi,&Jin-Jian Lu.(2018).Investigational Hypoxia-Activated Prodrugs: Making Sense of Future Development.Current Drug Targets,20.
MLA Min-Xia Su,et al."Investigational Hypoxia-Activated Prodrugs: Making Sense of Future Development".Current Drug Targets 20(2018).
Related Services
Recommend this item
Bookmark
Usage statistics
Export to Endnote
Google Scholar
Similar articles in Google Scholar
[Min-Xia Su]'s Articles
[Le-Le Zhang]'s Articles
[Zhang-Jian Huang]'s Articles
Baidu academic
Similar articles in Baidu academic
[Min-Xia Su]'s Articles
[Le-Le Zhang]'s Articles
[Zhang-Jian Huang]'s Articles
Bing Scholar
Similar articles in Bing Scholar
[Min-Xia Su]'s Articles
[Le-Le Zhang]'s Articles
[Zhang-Jian Huang]'s Articles
Terms of Use
No data!
Social Bookmark/Share
All comments (0)
No comment.
 

Items in the repository are protected by copyright, with all rights reserved, unless otherwise indicated.